FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387360986> ?p ?o ?g. }

• W4387360986 abstract "Abstract Disclosure: A. Golding: None. G. Correa: None. E. Valenzuela Sheker: None. R. Jiang: Employee; Self; Veracyte, Inc. Stock Owner; Self; Veracyte, Inc. Y. Hao: Employee; Self; Veracyte, Inc. Stock Owner; Self; Veracyte, Inc. Y. Liu: Employee; Self; Veracyte, Inc. Stock Owner; Self; Veracyte, Inc. J. Huang: Employee; Self; Veracyte, Inc. Stock Owner; Self; Veracyte, Inc. J.P. Klopper: Employee; Self; Veracyte, Inc. Stock Owner; Self; Veracyte, Inc. R.T. Kloos: Employee; Self; Veracyte, Inc. Stock Owner; Self; Veracyte, Inc. G.C. Kennedy: Employee; Self; Veracyte, Inc. Stock Owner; Self; Veracyte, Inc. D. Bimston: None. The 2015 ATA thyroid cancer risk stratification system is driven primarily by the extent of vascular and extrathyroidal extension, as well as lymph node metastases. The objectives of this study were to evaluate the prevalence of invasion and lymph node metastases in a cohort enriched with thyroid malignancies and provide a risk signature with a high negative predictive value ruling out these tumor features. Histopathology reports from Afirma Genomic Sequencing Classifier (GSC) algorithm training and from thyroid cancer patients managed at an integrative endocrine surgery community care practice (total 697 and ∼50% from each) were reviewed for invasion and metastases. An integer from 0-3 was assigned based on the extent of invasion (ranging from none to extensive extra-thyroidal) or extent of lymph node metastases (ranging from none to lateral node metastases). To develop predictive signatures for invasion/metastases, over 400 literature-derived expression-based signatures were evaluated; they cover a broad spectrum of molecular processes, including cancer hallmarks such as endothelial to mesenchymal transition, tumor microenvironment, immune-oncology, metabolism, and treatment sensitivity. Further, acknowledging that multiple complex molecular processes are associated with invasion/metastases, over 200 machine-learning (ML) models were trained within the repeated and nested cross-validation (CV) framework. They utilized these literature-derived signatures as well as differentially expressed genes between high and low risk of invasion/metastases as the basic building blocks. The application of top performing signatures among Bethesda (B) V/VI nodules as well as indeterminate thyroid nodules (ITN - BIII/IV) that are GSC-suspicious, showed that 40-50% of these lesions were marked as low risk for invasion/metastases. With a starting prevalence of 10.0% of high-level invasion (scored 2 or 3), 41.3% of the cohort is ruled out for clinically relevant invasion with a negative predictive value (NPV) of 97.6%. With a starting prevalence of 11.3% of high-level metastases (scored 2 or 3), 49.8% of the cohort is ruled out for clinically relevant metastases with an NPV of 98.6%. The rule-out capability represents more than 4-fold or 7-fold reduction in high-level invasion/metastases from the baseline prevalence, respectively. Expression-based signatures that confidently rule out tumor invasion and metastasis may help personalize the surgical approach for individuals. This may reduce excess surgery and overtreatment, optimizing the initial response to therapy and decreasing the rates of surgical complications and post-operative hypothyroidism. Presentation: Sunday, June 18, 2023" @default.
• W4387360986 created "2023-10-06" @default.
• W4387360986 creator A5003621039 @default.
• W4387360986 creator A5008423274 @default.
• W4387360986 creator A5008625477 @default.
• W4387360986 creator A5023363049 @default.
• W4387360986 creator A5043706524 @default.
• W4387360986 creator A5058413753 @default.
• W4387360986 creator A5067338175 @default.
• W4387360986 creator A5077549848 @default.
• W4387360986 creator A5078882032 @default.
• W4387360986 creator A5087489933 @default.
• W4387360986 creator A5093007102 @default.
• W4387360986 date "2023-10-01" @default.
• W4387360986 modified "2023-10-06" @default.
• W4387360986 title "OR32-03 mRNA Expression Based Tumor Behavior Prediction Models In Thyroid Nodules" @default.
• W4387360986 doi "https://doi.org/10.1210/jendso/bvad114.2058" @default.
• W4387360986 hasPublicationYear "2023" @default.
• W4387360986 type Work @default.
• W4387360986 citedByCount "0" @default.
• W4387360986 crossrefType "journal-article" @default.
• W4387360986 hasAuthorship W4387360986A5003621039 @default.
• W4387360986 hasAuthorship W4387360986A5008423274 @default.
• W4387360986 hasAuthorship W4387360986A5008625477 @default.
• W4387360986 hasAuthorship W4387360986A5023363049 @default.
• W4387360986 hasAuthorship W4387360986A5043706524 @default.
• W4387360986 hasAuthorship W4387360986A5058413753 @default.
• W4387360986 hasAuthorship W4387360986A5067338175 @default.
• W4387360986 hasAuthorship W4387360986A5077549848 @default.
• W4387360986 hasAuthorship W4387360986A5078882032 @default.
• W4387360986 hasAuthorship W4387360986A5087489933 @default.
• W4387360986 hasAuthorship W4387360986A5093007102 @default.
• W4387360986 hasBestOaLocation W43873609861 @default.
• W4387360986 hasConcept C126322002 @default.
• W4387360986 hasConcept C127413603 @default.
• W4387360986 hasConcept C142724271 @default.
• W4387360986 hasConcept C143998085 @default.
• W4387360986 hasConcept C204036174 @default.
• W4387360986 hasConcept C2779761222 @default.
• W4387360986 hasConcept C2780849966 @default.
• W4387360986 hasConcept C3020404979 @default.
• W4387360986 hasConcept C526584372 @default.
• W4387360986 hasConcept C71924100 @default.
• W4387360986 hasConcept C78519656 @default.
• W4387360986 hasConceptScore W4387360986C126322002 @default.
• W4387360986 hasConceptScore W4387360986C127413603 @default.
• W4387360986 hasConceptScore W4387360986C142724271 @default.
• W4387360986 hasConceptScore W4387360986C143998085 @default.
• W4387360986 hasConceptScore W4387360986C204036174 @default.
• W4387360986 hasConceptScore W4387360986C2779761222 @default.
• W4387360986 hasConceptScore W4387360986C2780849966 @default.
• W4387360986 hasConceptScore W4387360986C3020404979 @default.
• W4387360986 hasConceptScore W4387360986C526584372 @default.
• W4387360986 hasConceptScore W4387360986C71924100 @default.
• W4387360986 hasConceptScore W4387360986C78519656 @default.
• W4387360986 hasIssue "Supplement_1" @default.
• W4387360986 hasLocation W43873609861 @default.
• W4387360986 hasOpenAccess W4387360986 @default.
• W4387360986 hasPrimaryLocation W43873609861 @default.
• W4387360986 hasRelatedWork W1546692259 @default.
• W4387360986 hasRelatedWork W2321981960 @default.
• W4387360986 hasRelatedWork W2529645566 @default.
• W4387360986 hasRelatedWork W2571647860 @default.
• W4387360986 hasRelatedWork W2615818475 @default.
• W4387360986 hasRelatedWork W2748952813 @default.
• W4387360986 hasRelatedWork W3082927056 @default.
• W4387360986 hasRelatedWork W4250761926 @default.
• W4387360986 hasRelatedWork W4256299744 @default.
• W4387360986 hasRelatedWork W939259490 @default.
• W4387360986 hasVolume "7" @default.
• W4387360986 isParatext "false" @default.
• W4387360986 isRetracted "false" @default.
• W4387360986 workType "article" @default.